StemVacs-V / Res Nova Bio - LARVOL DELTA

Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST (PRNewswire) - "Therapeutic Solutions International, Inc...announced...the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies....Eutilex has developed an autologous immunotherapy for tumors which unleash the endogenous ability of T cells to selectively kill tumor cells, even in solid tumors, which will be commercially developed in the US by Eutilogics."

Licensing / partnership • Oncology

Therapeutic Solutions International Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer (PRNewswire) - “Therapeutic Solutions International…announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to initiate a clinical trial of its StemVacs-V immunotherapy in patients with metastatic breast cancer.”

IND • Breast Cancer • Oncology

Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC (PRNewswire) - "In a series of experiments tumor growth administration of dead tumor cells together with StemVacs-V resulted in potent immunological memory to the tumor cells, which could be transferred to immunologically naïve mice. Additionally, the experiments demonstrated killing tumor cells using conventional approaches such as chemotherapy, when performed together with StemVacs-V iPSC, led to the development of immunological memory towards the specific cancer."

Preclinical • Oncology

Therapeutic Solutions International Optimizes Targeting the "Achilles Heel" of Cancer Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC (PRNewswire) - "Therapeutic Solutions International, Inc...announced today new data demonstrating synergy between the Company's tumor blood vessel killing vaccine, StemVacs-V iPSC and specific immunological adjuvants...The data is part of a package being developed that the Company will send to the Food and Drug Administration (FDA) as part of its planning for an Investigational New Drug (IND) filing. Additionally, the data was incorporated in a patent application filed today."

Patent • Preclinical • Oncology

Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy (PRNewswire) - "Therapeutic Solutions International...announced today new data demonstrating an unexpected synergy between its inducible pluripotent stem cell (StemVacs-V iPSC) derived immunotherapy product with low dose cyclophosphamide in evoking potent immune mediated cancer regression...the Company demonstrated that its previously announced stem cell derived tumor endothelial-like cell vaccine enabled non-toxic doses of cyclophosphamide, an established chemotherapeutic agent, to induce significant reduction of established lung cancers, brain cancers, and skin cancers in animal models."

Preclinical • Brain Cancer • Lung Cancer • Oncology • Skin Cancer

Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V iPSC Derived Cancer Immunotherapeutic (PRNewswire) - "Therapeutic Solutions International, Inc...announced...new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies...Company scientists observed that mice bearing B16 melanoma treated with StemVacs-V possessed an increased T cell response towards the tumor associated antigen Brother of the Regulator of Imprinted Sites....Depletion of either T cells or natural killer cells in treated mice abrogated the cancer-reducing activity of StemVacs-V."

Preclinical • Oncology

Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V (PRNewswire) - "Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent and new data covering what the Company believes to be the first gene-modified, stem cell derived, universal donor dendritic cell cancer immunotherapy...The novel product, StemVacs-V™, is derived from a gene-modified stem cell which is designed to express proteins found selectively in cancer such as the antigen Brother of the Regulatory of Imprinted Sites (BORIS). Additionally, the stem cell is gene silenced for receptors which cancer generally uses to block immune cell activation."

Patent • Preclinical • Oncology